Terminated PHASE2 INTERVENTIONAL 3-arm NCT00290537

Phase II Study of ZD6474 in Advanced NSCLC

A Phase II Study of ZD6474 Alone and With Chemotherapy in Advanced NSCLC

Sponsor: AstraZeneca

Interventions Carboplatin Paclitaxel ZD6474

Updated 8 times since 2017 Last updated: Apr 13, 2016 Started: Jan 31, 2006 Primary completion: Apr 30, 2008 Completion: Apr 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Accrual was suboptimal and increasing the number of patients was not feasible.

Other terminated trials from AstraZeneca

See all terminations from AstraZeneca

Other Lung Cancer trials with similar outcome

Browse all Lung Cancer trials

Listed as NCT00290537, this PHASE2 trial focuses on Lung Cancer and remains terminated or withdrawn. Sponsored by AstraZeneca, it has been updated 8 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2022 [monthly]

Terminated PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States